AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.
about
MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancerEmerging role of Hippo pathway in gastric and other gastrointestinal cancersThe TEAD Family and Its Oncogenic Role in Promoting TumorigenesisAXL kinase as a novel target for cancer therapyThe two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatmentAn orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyTargeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer TherapyHippo/YAP pathway for targeted therapyGene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinomaThe role of the Hippo pathway in human disease and tumorigenesisAn oncogenic role of Agrin in regulating focal adhesion integrity in hepatocellular carcinomaPP1A-mediated dephosphorylation positively regulates YAP2 activityProteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomasGene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processesThe Hippo pathway controls border cell migration through distinct mechanisms in outer border cells and polar cells of the Drosophila ovary.TAZ expression as a prognostic indicator in colorectal cancer.Axl as a mediator of cellular growth and survivalAnti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinomaYAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of EnhancersCirculating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study.Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma.Expression of Yes-associated protein modulates Survivin expression in primary liver malignanciesYAP is a critical oncogene in human cholangiocarcinomaTargeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.MicroRNA-34a-5p enhances sensitivity to chemotherapy by targeting AXL in hepatocellular carcinoma MHCC-97L cells.Targeting Axl with an high-affinity inhibitory aptamer.Tead and AP1 Coordinate Transcription and Motility.Emerging roles of TEAD transcription factors and its coactivators in cancersThe hippo-yes association protein pathway in liver cancermiR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinomaYAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer.Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.Mammalian Hippo pathway: from development to cancer and beyond.The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway.The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy.
P2860
Q24339513-09A3DC24-1944-423D-A9DE-FC5A8CD1A23CQ26774473-2A2C1651-A8C2-47E4-8C42-DB745E817EA2Q26775126-D900DE17-E2E0-4A99-A209-3295CAFCF86EQ26863442-292AD866-B51F-4BF9-A5E1-1929EA40683BQ27025661-A89E3E15-24A1-48A1-9D62-C4F4B6405A96Q27310334-D146DDA9-39C7-42DF-A48D-6478DFE98866Q28070028-61095955-A554-41AC-A196-07BCA94D75F0Q28078129-2365436C-70B4-46E3-959D-D083842E4723Q28088294-41AA8806-1F5E-4C8E-AB5A-698C4E420D1FQ28740309-DC4394C4-18D7-4D70-A1CC-FC6EAF6B743AQ30433413-5340765A-5B55-461F-AD5B-24F4EB0E2248Q30619662-8D188A59-54D5-4FC8-833C-D5CA5F4B2C80Q34016621-641B0158-F012-49DB-A0E9-20E0D957B171Q34062012-F215B243-FC33-4F19-99A2-C3173E5CB70EQ34263230-15C1D4D4-983E-4DF9-99FF-6A18F1C0FF83Q34471565-5092CAC9-B7C5-4325-B78D-70431E83DD6AQ34571020-02E6AF45-CB2E-42C7-AA2D-8B7659685F7DQ34619118-50167867-AAE0-446E-842F-37F447B37F4EQ34988368-82F8113A-499D-4728-8C14-605F00C0B734Q35214708-212A3D94-3F6E-49DF-BFB4-CFE9FB407A8AQ35387908-0CD828CC-BEB3-4B89-90F4-B28D3C1CCEE4Q35669111-03C5543C-5CD1-4DFB-A942-0CAE13741321Q35752339-9CA0A745-0462-47CE-A8A4-2351099794E8Q35841111-68F1EE0C-298F-45F3-9F76-0521938EB27FQ36018500-E56B4647-690F-456B-8CEB-958725C3DC31Q36063654-FC8F429B-32F0-4EE1-937E-6446D6368C5CQ36232005-6E7A6C1C-D852-4D06-A8F8-E083FB50F29FQ36320570-D59DFEC4-DE59-480C-9FF3-917EF060130AQ36334535-5C8F93AD-4D53-451B-8D60-60F315E6970EQ36460465-3F78E104-B90C-4DF4-805C-4787A3E9DA4BQ36568116-3E54BC7C-330D-410E-8905-F5E800C10E08Q36901489-C2590C50-C050-4ADB-BDB8-9FD04B0FB4FEQ37108727-613D2CED-B904-468E-AC7D-1F15C29DA414Q37510658-6FF651E9-1277-49E4-AEFB-CF8BAD043800Q37668806-AA2FE928-40D6-4B1D-8D4F-3D0EF1A8F72BQ37718419-0C102CE3-7F68-4456-92BE-0FDA64DBDD5EQ37843031-D4FFC05C-0A74-4EBE-943F-0D4403E5224AQ38015671-4A36D15C-CAFD-4E2E-BE37-B4DA66A465FDQ38104686-B7D383EB-1D44-41E4-8716-E5E4FE704907Q38171966-1EDDCA73-94FA-4687-9199-9E1B1726A315
P2860
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
AXL receptor kinase is a media ...... s in hepatocellular carcinoma.
@ast
AXL receptor kinase is a media ...... s in hepatocellular carcinoma.
@en
type
label
AXL receptor kinase is a media ...... s in hepatocellular carcinoma.
@ast
AXL receptor kinase is a media ...... s in hepatocellular carcinoma.
@en
prefLabel
AXL receptor kinase is a media ...... s in hepatocellular carcinoma.
@ast
AXL receptor kinase is a media ...... s in hepatocellular carcinoma.
@en
P2093
P2860
P356
P1433
P1476
AXL receptor kinase is a media ...... ns in hepatocellular carcinoma
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2010.504
P407
P50
P577
2010-11-15T00:00:00Z